Raymund Tan
Psychiatry · Springfield, MONPI 1780876227
Payments from drug & device makers
Across 332 payments — averaging $19.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$2K
- Neurocrine Biosciences, Inc.$534
- Axsome Therapeutics, Inc.$520
- Alkermes, Inc.$516
- Otsuka America Pharmaceutical, Inc.$467
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$425
- plus $3K from 15 others
What the payments were for
- Food & beverage$6,46899%
- Education$781%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$247
- Azstarys$150
- ABILIFY ASIMTUFII$123
- ABILIFY MAINTENA$123
How this compares
$6,546 in reported general payments places this provider in the 85th percentile of 680 psychiatry providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 35 | $55,134 |
| Paliperidone ErPaliperidone | 31 | $10,397 |
| VyvanseLisdexamfetamine Dimesylate | 24 | $9,166 |
| FetzimaLevomilnacipran Hcl | 12 | $5,793 |
| Guanfacine Hcl ErGuanfacine Hcl | 24 | $1,800 |
| Guanfacine Hcl | 17 | $1,138 |
| Buspirone Hcl | 46 | $484 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 12 | $313 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 11 | $294 |
| Topiramate | 16 | $143 |
| Mirtazapine | 13 | $117 |
| Lamotrigine | 18 | $93 |
| Trazodone Hcl | 14 | $72 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $467 | $55,13435 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $138 | $9,16624 claims |
| AbbVieFetzima | $33 | $5,79312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 680 psychiatry providers in Missouri.
Other psychiatry in Springfield
- Alok JainSpringfield$64K
- Lorri DarrowSpringfield$47K
- Gregory MattingleySaint Charles$8.2M
- Junaid SyedSaint Louis$8M
- Eric CarbonellFestus$5.4M
- Ricky MofsenSaint Louis$4.9M
- Charles ConwaySaint Louis$3.8M
- Mohd MalikSaint Louis$2.8M
- Franco SicuroOlivette$2.3M
- Howard IlivickySaint Charles$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.